• news.cision.com/
  • Redsense/
  • Redsense Medical AB announces approval by University Health Network in Toronto, Canada , to conduct a follow up study of the Redsense Clamp prototype

Redsense Medical AB announces approval by University Health Network in Toronto, Canada , to conduct a follow up study of the Redsense Clamp prototype

Report this content

Redsense Medical AB has previously submitted a renewal application to conduct a follow up study on a prototype of the Company’s accessory product Redsense Clamp, which enables automatic stop of blood flow independent of the dialysis machine in use. This application has now been approved by the Research Ethics Board of the University Health Network, allowing the Company to proceed with the follow up study in Toronto.

Redsense has previously conducted a usability study on Redsense Clamp together with the UHS. In October 2018, Redsense announced the completion of this study, where Canadian home dialysis patients used the Redsense blood leakage alarm together with Redsense Clamp and successfully demonstrated proof of concept. The follow up is projected to be initiated in the fall of 2020.

This project is important to improve the patient safety of hemodialysis in general. We are now developing the product further, and we plan to have a new prototype ready in quarter three. We will then do a follow up study during the winter,” says Redsense Medical’s CEO Patrik Byhmer: “UHS’s approval is the prerequisite and brings us one step closer towards faster and more reliable detection of blood leakage from venous needle dislodgement for all hemodialysis patients.”

About Redsense Clamp
The Redsense Clamp product was introduced in 2018 and is currently under development. Redsense Clamp is an accessory to the company’s blood leakage alarm NS enables the blood flow to be stopped automatically regardless of which dialysis machine is used. The purpose of Redsense Clamp is to enable the Redsense blood leakage alarm to offer the highest possible patient safety even when it is used together with dialysis machine without a direct connection to the alarm. The Company has projected commercialization to commence in Canada and Europe in 2021.

For more information, please contact:

Patrik Byhmer, CEO Redsense Medical AB (publ)

Phone: +46 35 10 60 30




Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovationused for monitoring and alarm in the case of blood leakage in connection with hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.